Clinical Trials Browser

Phase 3 × Completed × Genitourinary × Clear all

NCT02044354 2026-04-01

CABA-DOC

Phase 3 Completed

Metastatic Castration-resistant Prostate Cancer

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT03142334 2026-03-10

KEYNOTE-564

Phase 3 Completed

994 enrolled 10 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3 Completed

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT00063882 2026-03-05

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Completed

588 enrolled 34 charts

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Phase 3 Completed

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT06235099 2026-02-18

Solar-Recur

Phase 3 Completed

Prostatic Neoplasms

NCT07413120 2026-02-17

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Phase 3 Completed

Adenocarcinoma, Kidney Neoplasms, Prostatic Neoplasms

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 2 FDA

Carcinoma, Renal Cell

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01809691 2025-12-31

S1216

Phase 3 Completed

1,313 enrolled 22 charts

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT00309985 2025-12-11

CHAARTED

Phase 3 Completed

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 5 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT04394975 2025-11-28

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase 3 Completed

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Phase 3 Completed

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04838613 2025-10-20

GuidePath

Phase 3 Completed

190 enrolled 25 charts

Prostatic Neoplasms, Recurrence

NCT01812369 2025-10-06

VESPER

Phase 3 Completed

Urinary Bladder Neoplasms

NCT04186845 2025-09-22

Spotlight

Phase 3 Completed

391 enrolled 30 charts

Disease, Prostatic Neoplasms

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05590793 2025-09-09

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Phase 3 Completed

195 enrolled 19 charts

Prostatic Neoplasms

NCT04534075 2025-09-08

FIDURA

Phase 3 Completed

GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Flatulence, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT00930033 2025-09-05

CARMENA

Phase 3 Completed

Carcinoma, Renal Cell

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase 3 Completed

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05605964 2025-08-17

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Phase 3 Completed

Prostatic Neoplasms

NCT04527991 2025-08-03

TROPiCS-04

Phase 3 Completed

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 2 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT05458856 2025-07-25

TriptoSwitch

Phase 3 Completed

147 enrolled 14 charts

Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

Phase 3 Completed

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05547386 2025-07-18

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Phase 3 Completed

163 enrolled 3 charts

Prostatic Neoplasms

NCT04742361 2025-07-15

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 2 FDA

Carcinoma, Renal Cell

NCT04100018 2025-06-12

CheckMate 7DX

Phase 3 Completed

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT00667069 2025-06-05

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT06984159 2025-05-22

The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

Phase 3 Completed

Advanced Prostate Cancer

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03936218 2025-04-17

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Phase 3 Completed

Advanced Prostate Cancer

NCT01220869 2025-04-13

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Phase 3 Completed

110 enrolled 11 charts

Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00720941 2025-03-30

COMPARZ

Phase 3 Completed

1,110 enrolled 27 charts

Carcinoma, Renal Cell